Ibrutinib

Common brands: Imbruvica, Rituxan, Aloprim, Allopurinol, Venclexta

Top reporter: Pharmacyclics Llc

Kinase Inhibitor [EPC]CD20-directed Cytolytic Antibody [EPC]Corticosteroid [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]Xanthine Oxidase Inhibitor [EPC]
79,578
Total Reports
41,211
Serious Reports
13,537
Death Reports
30
Reported Reactions
Death Report Ratio: High (17.01%)

Patient Demographics

Male
45,079
Female
28,114

Reported Adverse Reactions (30)

Side effects reported in FDA adverse event reports for Ibrutinib.

# Reaction Reports % of Total
1 DEATH 8,466
11.2%
2 OFF LABEL USE 5,942
7.9%
3 FATIGUE 4,708
6.2%
4 DIARRHOEA 4,152
5.5%
5 ATRIAL FIBRILLATION 3,866
5.1%
6 PNEUMONIA 3,237
4.3%
7 CONTUSION 2,792
3.7%
8 INCORRECT DOSE ADMINISTERED 2,778
3.7%
9 FALL 2,502
3.3%
10 ASTHENIA 2,339
3.1%
11 NAUSEA 2,297
3.0%
12 ARTHRALGIA 2,198
2.9%
13 RASH 2,139
2.8%
14 HAEMORRHAGE 1,993
2.6%
15 DISEASE PROGRESSION 1,970
2.6%
16 PYREXIA 1,836
2.4%
17 MUSCLE SPASMS 1,765
2.3%
18 COVID-19 1,730
2.3%
19 DIZZINESS 1,722
2.3%
20 ANAEMIA 1,697
2.2%
21 DYSPNOEA 1,656
2.2%
22 PLATELET COUNT DECREASED 1,636
2.2%
23 PAIN 1,631
2.2%
24 HOSPITALISATION 1,601
2.1%
25 PERIPHERAL SWELLING 1,534
2.0%
26 HEADACHE 1,522
2.0%
27 DRUG INEFFECTIVE 1,513
2.0%
28 NEUTROPENIA 1,493
2.0%
29 INFECTION 1,485
2.0%
30 THROMBOCYTOPENIA 1,449
1.9%

Important Disclaimer

FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.